Regeneron's Melanoma Drug Fails Late-Stage Trial, Shares Drop 11.8%
REGN sits 32% above its 52-week low of $476.487.
Summary
Regeneron Pharmaceuticals announced that its experimental fianlimab-cemiplimab combination treatment for advanced melanoma failed to meet its primary endpoint in a late-stage trial. The drug did not achieve statistical significance in improving progression-free survival (PFS) compared to Merck's Keytruda, despite showing a numeric improvement of 5.1 months. This represents a significant setback for Regeneron's pipeline, as a late-stage failure for a potential new treatment in a serious indication like advanced melanoma impacts future revenue projections and R&D investment. The news led to an 11.8% premarket decline in Regeneron's shares. Investors will now watch for further details on the trial data and any potential strategic shifts in the company's oncology pipeline.
At the time of this announcement, REGN was trading at $627.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $73.2B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.